Targeting specific receptors to improve treatment for glioblastoma
“Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response”
This study is looking at how new treatments that target specific receptors in brain tumors might make current therapies for glioblastoma, like chemotherapy and radiation, work better, with the hope of improving outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10931564 on NIH RePORTER |
What this research studies
This research investigates how targeting the NR4A1 and NR4A2 receptors can enhance the effectiveness of existing treatments for glioblastoma, a common and aggressive brain cancer. The approach involves using novel compounds that inhibit these receptors, which are believed to contribute to treatment resistance. By reprogramming the tumor microenvironment and boosting immune responses, the research aims to improve patient outcomes when combined with standard therapies like temozolomide and radiation. Patients may be monitored for changes in tumor response and immune activity as part of the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who have not responded adequately to standard treatments.
Not a fit: Patients with glioblastoma who are not eligible for standard therapies or have other significant health issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and treatment responses for patients with glioblastoma.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in other cancers, suggesting potential for success in glioblastoma treatment.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Rostomily, Robert C — Methodist Hospital Research Institute
- Study coordinator: Rostomily, Robert C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.